Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › insulin degludec

insulin degludec

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of insulin degludec

64 trials tracked of insulin degludec: 57 in phase 3 or 4 and 30 with published results. The most-cited published study has 568 citations.

64Trials tracked
57Phase 3 & 4
0Recruiting
30With published results
Phase distribution
Phase 4 6 Phase 3 51 Phase 2 7
  1. Phase 3 A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events Completed · 568 cited
  2. Phase 3 Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes Completed · 362 cited
  3. Phase 3 A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes Completed · 254 cited
  4. Phase 3 A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes Completed · 220 cited
  5. Phase 3 A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes Completed · 207 cited
  6. Phase 3 A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 3) Completed · 134 cited
Show 44 more trials
  1. Phase 3 A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Use Daily Insulin Completed · 133 cited
  2. Phase 3 A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6) Completed · 101 cited
  3. Phase 3 A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes Completed · 77 cited
  4. Phase 3 A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before Completed · 76 cited
  5. Phase 3 A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs Completed · 70 cited
  6. Phase 3 A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes Completed · 69 cited
  7. Phase 3 Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes Completed · 67 cited
  8. Phase 3 Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes Completed · 56 cited
  9. Phase 3 A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time Completed · 51 cited
  10. Phase 3 Research Study Comparing Insulin Degludec to Insulin Detemir, Together With Insulin Aspart, in Pregnant Women With Type 1 Diabetes Completed · 49 cited
  11. Phase 3 A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy Completed · 44 cited
  12. Phase 3 The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification Completed · 32 cited
  13. Phase 3 A Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs Completed · 31 cited
  14. Phase 4 A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study Completed · 29 cited
  15. Phase 3 Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 Diabetes Completed · 26 cited
  16. Phase 3 A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus. Completed · 24 cited
  17. Phase 3 A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin Completed · 21 cited
  18. Phase 3 A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Completed · 16 cited
  19. Phase 3 A Trial Investigating the Efficacy and Safety of Flexible vs. Fixed Dosing and Simple vs. Stepwise Titration With Once Daily (OD) Insulin Degludec in Inadequately Treated Subjects With Type 2 Diabetes Completed · 14 cited
  20. Phase 3 A Study of LY900014 in Participants With Type 1 Diabetes Completed · 14 cited
  21. Phase 4 Comparison of Insulin Degludec With Insulin Glargine U100 for Adults With Type 1 Diabetes Crossing Multiple Time Zones. Completed · 6 cited
  22. Phase 4 Afrezza With Basal Combination (ABC): Afrezza® Combined With AID Pump or Insulin Degludec in Adults With Type 1 Diabetes Completed · 6 cited
  23. Phase 4 Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D Completed · 5 cited
  24. Phase 3 A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes Completed · 3 cited
  25. Phase 4 Effect of Insulin Degludec Versus Insulin Glargine on Glycemic Variability in Patients With Type 2 Diabetes Mellitus Completed
  26. Phase 4 Comparison of Glargine to Degludec Insulin Transition With or Without a Bridging Glargine Dose Completed
  27. Phase 3 A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD) Completed
  28. Phase 3 A Study Comparing LY900014 to Insulin Lispro (Humalog) in Children and Adolescents With Type 1 Diabetes Completed
  29. Phase 3 A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 2 Diabetes Completed
  30. Phase 3 Research Study to Compare a New Medicine "Fast-acting Insulin Aspart" to Another Medicine "Insulin Aspart" in Chinese People With Diabetes Completed
  31. Phase 3 A Trial Comparing Efficacy and Safety of Insulin Degludec and Insulin Glargine in Insulin naïve Subjects With Type 2 Diabetes Completed
  32. Phase 3 Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin Completed
  33. Phase 3 Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes Completed
  34. Phase 3 A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice Daily Completed
  35. Phase 3 Comparison of NN1250 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes Completed
  36. Phase 3 Comparison of NN1250 With Sitagliptin in Subjects With Type 2 Diabetes Never Treated With Insulin Completed
  37. Phase 3 Comparison of Two Insulin Degludec Formulations in Subjects With Type 2 Diabetes Mellitus Completed
  38. Phase 3 Comparison of NN1250 Plus Insulin Aspart With Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes Completed
  39. Phase 3 Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes Completed
  40. Phase 3 Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes Completed
  41. Phase 3 Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes Completed
  42. Phase 3 A Trial Comparing the Efficacy of Insulin Degludec With Insulin Glargine on Glycaemic Control Using Continuous Glucose Monitoring in Patients With Type 1 Diabetes Completed
  43. Phase 3 Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes Completed
  44. Phase 3 A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus Completed

Showing the 50 most-cited and recently-updated of 64 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Insulin degludec/liraglutide ranks highest for HbA1c reduction with SUCRA value of 89.4%
Nutrition & Obesity Medicine Sys. Review
Insulin degludec/liraglutide ranks highest for HbA1c reduction with SUCRA value of 89.4% Comparing Combination Diabetes Drugs for Blood Sugar Control
This network meta-analysis evaluated 12,815 patients with type 2 diabetes to compare fixed-ratio combination products and their individual c…
A review of 12,815 patients found that insulin degludec/liraglutide may be best for lowering blood sugar, but has more side effects than oth…
Jun 4, 2026